| Dr David Curt Brown, PHD | |
|
4447 E Broadway Rd Ste 108, Mesa, AZ 85206-2018 | |
| (480) 641-9700 | |
| (480) 641-9751 |
| Full Name | Dr David Curt Brown |
|---|---|
| Gender | Male |
| Speciality | Marriage & Family Therapist |
| Location | 4447 E Broadway Rd Ste 108, Mesa, Arizona |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467578427 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | LMFT-0148 (Arizona) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Curt Brown, PHD 4447 E Broadway Rd Ste 108, Mesa, AZ 85206-2018 Ph: (480) 641-9700 | Dr David Curt Brown, PHD 4447 E Broadway Rd Ste 108, Mesa, AZ 85206-2018 Ph: (480) 641-9700 |
News Archive
Patients who have cartilage damage in their knees often experience pain and are unable to engage in sports and other activities they enjoy. Two studies at Hospital for Special Surgery find that cartilage restoration procedures are a viable treatment option for patients over 40 years old.
Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.
Meningiomas are the most common benign intracranial tumors, and in individuals ages 35 and older, the most common type of brain tumor diagnosed. They most often occur in people between the ages of 40 and 70.
Influenza vaccination reduces the risk of all-cause death, myocardial infarction, or stent thrombosis at 12 months in hospitalized patients with myocardial infarction or high-risk coronary disease, according to late breaking research presented in a Hot Line session today at ESC Congress 2021.
Schering-Plough Corporation has announced plans to initiate two global Phase III large-scale clinical outcomes trials for its novel selective oral antiplatelet therapy, the thrombin receptor antagonist (TRA) SCH 530348.
› Verified 6 days ago
Natasha Natasha Hatch, Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 1234 S Power Rd Ste 100, Mesa, AZ 85206 Phone: 602-633-5032 | |
Mrs. Kylie Nelson, Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 2929 N Power Rd, Suite 101, Mesa, AZ 85215 Phone: 928-542-6700 | |
Catherine Jean Newell, LAMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 6402 E Superstition Springs Blvd, Suite 208, Mesa, AZ 85206 Phone: 480-331-7358 Fax: 480-558-3020 | |
Devan Anne Hunt, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 2500 S Power Rd Ste 120, Mesa, AZ 85209 Phone: 480-382-1257 | |
Dr. Matthew Andrew Rundio, D.MIN, MSMFT, LAMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 4864 E Baseline Rd Ste 106, Mesa, AZ 85206 Phone: 480-877-1486 | |
Jacob Ybarra, Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 1745 S Alma School Rd Ste 230, Mesa, AZ 85210 Phone: 480-668-8301 | |
Eric J Henley, LAMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 3048 E Baseline Rd Ste 108, Mesa, AZ 85204 Phone: 480-710-6435 |